DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PD-1+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in the PD-1 Non-small cell lung cancer market.
Discover the latest drugs and treatment options in the PD-1+ NSCLC Pipeline @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight
Key Takeaways from the PD-1+ NSCLC Pipeline Report
- On June 26, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.
- On June 24, 2026- Incyte Corporation conducted a phase 3 study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- On June 22, 2026- AbbVie initiated a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
- On June 15, 2026- Pfizer conducted a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
- On June 11, 2026- Iovance Biotherapeutics Inc. initiated a phase 1/2 study is the first-in-human study of IOV-4001, a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product. IOV-4001 is expected to have antitumor activity through its capacity to directly target and kill tumor cells in a manner that is similar to non-genome-edited TIL, but with the potential for enhanced antitumor activity due to disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1).
- On June 02, 2026- Genmab conducted a Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.
- DelveInsight’s PD-1+ NSCLC Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1+ NSCLC treatment.
- The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
- Promising PD-1+ NSCLC Pipeline Therapies such as AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ PD-1+ NSCLC Treatment Drugs
Non-Small Cell Lung Cancer (NSCLC) Overview
Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC). Blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1 has achieved robust responses and improved survival for patients with locally advanced/metastatic NSCLC in preclinical and clinical studies. InPD-1 is a Type I transmembrane protein and is expressed on T-cells, B-cells, nature killer cells, activated monocytes, and dendritic cells (DCs). PD-L1 and PD-L2, two ligands of PD-1, are also Type I transmembrane proteins and differ in their expression patterns. PD-L1 can be expressed on T-cells, B-cells, DCs, macrophages, a wide variety of nonhematopoietic cells, and also on TCs.11–13 PD-1 and its ligands consist of a signal sequence.
PD-1+ NSCLC Emerging Drugs Profile
- Zimberelimab: Arcus Biosciences
Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin’s lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.
- PM8002: Biotheus
PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.
- RPH075: R-Pharm
R-Pharm’s pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.
The PD-1+ NSCLC Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of PD-1+ NSCLC with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1+ NSCLC Treatment.
- PD-1+ NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- PD-1+ NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1+ NSCLC market
Explore groundbreaking therapies and clinical trials in the PD-1+ NSCLC Marketed and Pipeline Drugs @ New PD-1+ NSCLC Drugs
PD-1+ NSCLC Companies
Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
PD-1+ NSCLC Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ PD-1+ NSCLC Market Drivers and Barriers
Scope of the PD-1+ NSCLC Pipeline Report
- Coverage- Global
- PD-1+ NSCLC Companies- Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others.
- PD-1+ NSCLC Pipeline Therapies- AZD2936, Cisplatin, Carboplatin, PF-06801591, AK112, Chidamide, Envafolimab and others.
- PD-1+ NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- PD-1+ NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight’s in-depth pipeline report today! @ PD-1+ NSCLC Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- PD-1 Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Zimberelimab: Arcus Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RPH075: R-Pharm
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Collaborations Assessment- Licensing / Partnering / Funding
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Unmet Needs
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight